PBIC was established in 2015 as a dedicated facility for the production of Active Pharmaceutical Ingredients (APIs) and associated chemicals such as intermediates. The site was commissioned in January 2015 and production started in April 2016.

PBIC contracted with Tecnologia Sicurezza Ambiente (TSA) , Padova, Italy, to design and build this state-of-the-art facility. T.S.A. is an engineering firm specializing in the design of pharmaceutical, chemical and food facilities, water systems and waste treatment plants.

PBIC has a range of custom synthesis contracts with pharmaceutical companies including large tonnage production of APIs used in the treatment of HCV. PBIC collaborated with Chemelectiva , Novara, Italy in the development of the site’s first API – SOFOSBUVIR – a Hepatitis C Virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated in the treatment of chronic hepatitis C infection in combination with NS5A inhibitors. PBIC initiated collaboration with Chemelectiva , Novara, Italy for the development of RAVIDASVIR – a Hepatitis C Virus (HCV) NS5A inhibitor developed for the treatment of chronic Hepatitis C infection with Sofosbuvir.